Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescent (ages 10 - 17 years) boys or girls weighing at least 88 lbs (40 kg).~* Subjects must have high cholesterol (low density lipoprotein cholesterol \[LDL-C\] more than 159 mg/dL or 4.1 mmol/L) and a family history of high cholesterol.~Exclusion Criteria:~* Subjects diagnosed with delayed puberty.~* Subjects who are sensitive to simvastatin and/or ezetimibe.~* Subjects who drink alcohol excessively or who have a history of alcohol or drug abuse within the past 2 years.~* Subjects who are known to be HIV positive, are undergoing LDL apheresis or plasma apheresis, or have had a partial ileal bypass.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pooled subjects who received ezetimibe with simvastatin (Type: EXPERIMENTAL): Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
- Pooled subjects who received simvastatin monotherapy (Type: ACTIVE_COMPARATOR): Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).